Head of Research, Krungthai XSpring

Waraporn Wiboonkanarak

Head of Research

A full service Thai brokerage

Krungthai XSpring

Krungthai XSpring is a full service broker. The company provides a wide range of investment services such as Securities Brokerage, Derivative Agent Business, Securities Borrowing and Lending, Securities Trading, Underwriting, Financial Advisory, Wealth Advisory, Private Fund Management and International Markets Securities Trading. 

In terms of credibility, Fitch Ratings has assigned Krunghtai XSpring a long-term rating of AA- and a national short-term rating of F1+ with stable outlook.

Equity Bottom-Up

<ul><li>Technically, the SET Index is expected to move sideways up, with the resistance at 1,301/1,306 points (25-day EMA) and the support at 1,287/1,281 points.</li><li>In the short term, however, the index is in an uptrend, continuing to rise from the year's low of 1,273.17 points on August 5.</li><li>We recommend buying stocks in the food, tourism, agriculture, energy, retail, and healthcare sectors, as their 1H24 earnings performances appear strong, with 12M net profit forecasts being revised upward.</li></ul>

Technically, the SET Index is expected to move sideways up, with the resistance at 1,301/1,306 points (25-day EMA) and the support at 1,287/1,281 points.In the short term, however, the index is in an uptrend, continuing to rise from the year's low of 1,273.17 points on August 5.We recommend buying stocks in the food, tourism, agriculture, energy, retail, and healthcare sectors, as their 1H24 earnings performances appear strong, with 12M net profit forecasts being revised upward.

<ul><li>Technically, the SET Index is expected to move sideways up, with the resistance at 1,324/1,332 points and the support at 1,314/1,310 points.</li><li>The market assigns a 45% probability that the BoE will cut interest rates by 25 bps to 5.0%.</li><li>The ISM manufacturing PMI is expected to increase to 48.8 (vs. June at 48.5), while the S&P Global manufacturing PMI is expected to drop sharply to 49.5 (vs. June at 51.6).</li></ul>

Technically, the SET Index is expected to move sideways up, with the resistance at 1,324/1,332 points and the support at 1,314/1,310 points.The market assigns a 45% probability that the BoE will cut interest rates by 25 bps to 5.0%.The ISM manufacturing PMI is expected to increase to 48.8 (vs. June at 48.5), while the S&P Global manufacturing PMI is expected to drop sharply to 49.5 (vs. June at 51.6).

July's Manufacturing Figures in the US, EU and China and Earnings Results

<ul><li>Technically, the SET Index is expected to move sideways, with the support at 1,360/1,350 points (1/2 and 1/3 of the Fibonacci range of 1,325-1,380 points) and the resistance at 1,380/1,385 points.</li><li>Overall, the index is still moving in an uptrend toward testing the resistance of the down channel range at 1,380 points.</li><li>As for the short-term picture, a new buy signal will occur when the index can break through the key resistance at the 50-day EMA/75-day EMA at 1,375-1,380 points or higher; otherwise, it will move sideways or retrace toward 1,330 points if it falls below the key support at 1,350 points.</li></ul>

Technically, the SET Index is expected to move sideways, with the support at 1,360/1,350 points (1/2 and 1/3 of the Fibonacci range of 1,325-1,380 points) and the resistance at 1,380/1,385 points.Overall, the index is still moving in an uptrend toward testing the resistance of the down channel range at 1,380 points.As for the short-term picture, a new buy signal will occur when the index can break through the key resistance at the 50-day EMA/75-day EMA at 1,375-1,380 points or higher; otherwise, it will move sideways or retrace toward 1,330 points if it falls below the key support at 1,350 points.

Keep a Close Watch on Fed Chair's Speech, Corporate Earnings and US PPI

Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Laboratory Corporation of America Holdings / Equity Bottom-Up

Laboratory Corporation of America Holdings (LH US)

Laboratory Corporation of America Holdings

<ul><li>Laboratory Corporation of America Holdings (LabCorp) has seen significant growth in its first quarter of 2024 and continues to show promise for the rest of the year.</li><li>The total revenue for the quarter was $3.2 billion with adjusted earnings per share at $3.68, which represents a 5% increase in enterprise revenue from the first quarter of 2023.</li><li>Within the revenue growth, the Diagnostic Laboratories business accounted for a 4% increase, while Biopharma revenue rose 8%.</li></ul>

Laboratory Corporation of America Holdings (LabCorp) has seen significant growth in its first quarter of 2024 and continues to show promise for the rest of the year.The total revenue for the quarter was $3.2 billion with adjusted earnings per share at $3.68, which represents a 5% increase in enterprise revenue from the first quarter of 2023.Within the revenue growth, the Diagnostic Laboratories business accounted for a 4% increase, while Biopharma revenue rose 8%.

Laboratory Corporation of America (LabCorp): Will The Acquisition of Invitae Be A Game Changer? - Major Drivers

<ul><li>Laboratory Corporation of America Holdings' Q4 2023 highlighted a robust performance, driven by strong base business revenue growth.</li><li>Discussing Q4 results, revenues reached $3 billion, adjusted earnings per share was $3.30, and free cash flow from operations, excluding spin-related items, was $422 million.</li><li>Enterprise revenue grew by 4% compared to Q4 2022, led by an 8% growth in the Diagnostics business and 7% growth in the Biopharma business.</li></ul>

Laboratory Corporation of America Holdings' Q4 2023 highlighted a robust performance, driven by strong base business revenue growth.Discussing Q4 results, revenues reached $3 billion, adjusted earnings per share was $3.30, and free cash flow from operations, excluding spin-related items, was $422 million.Enterprise revenue grew by 4% compared to Q4 2022, led by an 8% growth in the Diagnostics business and 7% growth in the Biopharma business.

Laboratory Corporation of America (LabCorp): Significant Growth Momentum In The Diagnostics & Women's Health Can Revolutionize Growth? - Major Drivers

United States

Laboratory Corporation of America Holdings is a clinical laboratory company that offers clinical laboratory tests used by the medical profession in routine testing, patient diagnosis, and in the monitoring and treatment of disease. The Company develops specialty testing operations, such as oncology testing, HIV genotyping and phenotyping, diagnostic genetics and clinical trials.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Laboratory Corporation of America Holdings (LH US)

Today's Dominant Ideas

Technically, the SET Index is expected to move sideways up, with the resistance at 1,301/1,306 points (25-day EMA) and the support at 1,287/1,281...

Krungthai XSpring

July's Manufacturing Figures in the US, EU and China and Earnings Results

Technically, the SET Index is expected to move sideways up, with the resistance at 1,324/1,332 points and the support at 1,314/1,310 points. The...

Krungthai XSpring

Keep a Close Watch on Fed Chair's Speech, Corporate Earnings and US PPI

Technically, the SET Index is expected to move sideways, with the support at 1,360/1,350 points (1/2 and 1/3 of the Fibonacci range of 1,325-1,380...

Krungthai XSpring

Laboratory Corporation of America (LabCorp): Will The Acquisition of Invitae Be A Game Changer? - Major Drivers

Laboratory Corporation of America Holdings (LabCorp) has seen significant growth in its first quarter of 2024 and continues to show promise for...

Baptista Research

Laboratory Corporation of America (LabCorp): Significant Growth Momentum In The Diagnostics & Women's Health Can Revolutionize Growth? - Major Drivers

Laboratory Corporation of America Holdings' Q4 2023 highlighted a robust performance, driven by strong base business revenue growth. Discussing Q4...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)